anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an anti-CD 19 humanized antibody and a preparation method and application thereof, wherein the antibody comprises a humanized heavy chain variable region VH and a humanized light chain variable region VL, and the VH and VL are respectively composed of a determinant complementary region and a framework region; the determinant complementarity regions of said VH and said VL are each composed of CDR1, CDR2, and CDR 3; the amino acid sequence of CDR1 of VH is selected from SEQ ID NO. 1-4; the amino acid sequence of CDR2 of VH is selected from SEQ ID NO. 5-8; the amino acid sequence of CDR3 of VH is selected from SEQ ID NO. 9-12; the amino acid sequence of CDR1 of VL is selected from SEQ ID NO. 13-16; the amino acid sequence of CDR2 of VL is selected from SEQ ID NO. 17-20; the amino acid sequence of CDR3 of VL is selected from SEQ ID NO. 21-24; the humanization degree is high, and the affinity is high.
The present invention is generally directed to a method of increasing testosterone levels in a subject comprising; administration of testosterone or analogue thereof along with an ornithine decarboxylase (ODC) inhibitor. The method selectively promotes beneficial effects of testosterone, while preventing side effects associated with testosterone administration. The present invention also directed to pharmaceutical composition and kits comprising testosterone or analogue thereof; ornithine decarboxylase inhibitors. The composition selectively promotes beneficial effects of testosterone, while preventing side effects of testosterone administration. In some embodiments, the present invention relates to a method of treatment of low testosterone levels in a subject by administrating testosterone and ODC inhibitor while preventing side effects associated with testosterone administration. The method and composition of the invention particularly prevents potential adverse effects on the prostate in men and virilization in women.
PROBLEM TO BE SOLVED: To obtain the subject sedative capable of providing sedative effects simply by vaporizing and inhaling thereof without any fear of physically or psychologically loading a user by including a trialkoxybenzene. SOLUTION: This sedative is obtained by including a trialkoxybenzene represented by the formula (R1 to R3 are each an alkoxy and preferably CH3 or C2H5) as an active ingredient. Trimethoxybenzene (e.g. 1,3,5- trimethoxybenzene) is preferred as the trialkoxybenzene. The trialkoxybenzene has a phenolic sweetness and a spicy woody aroma. The sedative is included as an active ingredient to afford a sedative perfume composition such as a perfume, a shampoo, rinses, an aromatic agent or a bathing agent. The content of the trialkoxybenzene in the composition is preferably 0.5-50 wt.%, more preferably 1-20 wt.%.
BACKGROUND: Postoperative delirium (POD) is a common form of postoperative brain dysfunction, especially in the elderly. However, its risk factors remain largely to be determined. This study aimed to investigate whether (1) preoperative diabetes is associated with POD after elective orthopedic surgery and (2) intraoperative frontal alpha power is a mediator of the association between preoperative diabetes and POD.
METHODS: This was a prospective matched cohort study of patients aged 60 years or more, with a preoperative diabetes who underwent elective orthopedic surgery. Nondiabetic patients were matched 1:1 to diabetic patients in terms of age, sex, and type of surgery. Primary outcome was occurrence of POD, assessed using the 3-minute Diagnostic Confusion Assessment Method (3D-CAM) once daily from 6 pm to 8 pm during the postoperative days 1-7 or until discharge. Secondary outcome was the severity of POD which was assessed for all participants using the short form of the CAM-Severity. Frontal electroencephalogram (EEG) was recorded starting before induction of anesthesia and lasting until discharge from the operating room. Intraoperative alpha power was calculated using multitaper spectral analyses. Mediation analysis was used to estimate the proportion of the association between preoperative diabetes and POD that could be explained by intraoperative alpha power.
RESULTS: A total of 138 pairs of eligible patients successfully matched 1:1. After enrollment, 6 patients in the diabetes group and 4 patients in the nondiabetes group were excluded due to unavailability of raw EEG data. The final analysis included 132 participants with preoperative diabetes and 134 participants without preoperative diabetes, with a median age of 68 years and 72.6% of patients were female. The incidence of POD was 16.7% (22/132) in patients with preoperative diabetes vs 6.0% (8/134) in patients without preoperative diabetes. Preoperative diabetes was associated with increased odds of POD after adjustment of age, sex, body mass index, education level, hypertension, arrhythmia, coronary heart disease, and history of stroke (odds ratio, 3.2; 95% confidence interval [CI], 1.4-8.0; P = .009). The intraoperative alpha power accounted for an estimated 20% (95% CI, 2.6-60%; P = .021) of the association between diabetes and POD.
CONCLUSIONS: This study suggests that preoperative diabetes is associated with an increased risk of POD in older patients undergoing major orthopedic surgery, and that low intraoperative alpha power partially mediates such association.
The current commonly used for distal gastri cancer in gastrointestinal anastomosis is Roux-en-Y. However, the complications after Roux-en-Y reach an incidence of over 30% which involve nausea, vomiting, and abdominal distension. The underlying mechanism might be the result of interruption of intestine peristalsis. In 2013, Kim reported total laparoscopic uncut Roux-en-Y anastomosis could reduce Roux stasis syndrome incidence by keeping the continuity of jejunum. In September 2014, we carried out this operation in 30 cases in our centre. Our previous results showed that this operation had a low postoperative complication and short hospitalization time, indicating uncut Roux-en-Y anastomosis might be a safe procedure. However, some limitations are noticed. The report from South Korea is a retrospective study and the evaluation of QOL is certain subjective. Here, we aimed to perform the first randomized controlled clinical study on uncut Roux-en-Y anastomosis to improve QOL of patients after laparoscopic distal gastrectomy. The primary aim is to determine whether uncut Roux-en-Y anastomosis improve the quality of life of patients after laparoscopic distal gastrectomy.
Each child will receive 16 training sessions (8 weeks of training @ 2 sessions per week, approximately 30-45 minutes of interaction time per session) from an expert trainer and parent guidance using telehealth or face-to-face interactions. Within each session, the child will engage in seated play focused on reading, building, and art-craft activities. Based on feasibility, parents will be given appropriate supplies and trained to promote similar activities at home 1-2 days/week.
PURPOSE:To obtain an emulsion useful as a base for a cosmetic and a medicine, having excellent stability in acidity at a high temperature and safety in terms of hygiene, by dispersing a polyisobutylene having a specific viscosity-average molecular weight and specific two kinds of emulsifying agents into water. CONSTITUTION:This emulsion is composed of (A) 100 pts.wt. of a polyisobutylene having 10,000-70,000 viscosity-average molecular weight, (B) 1-40 pts.wt. of a polyoxyethylene polyoxypropylene block polymer of the formula [(a), (b) and (c) are 1-700] having 1,500-80,000 number-average molecular weight and (C) 1-20 pts.wt. of a sucrose fatty acid ester and the rest of water. Solid content of this emulsion is 1-75wt.%. The component B, for example, is obtained by polymerizing propylene oxide to give a polypropylene glycol and subjecting ethylene oxide to addition polymerization to active hydrogens at both ends of the compound.
The purpose of this study is to test the efficacy of an online, self-guided ACT-based narrative intervention for adults currently taking antidepressant medication. To test the effects of LifeStories on depression severity, quality of life, general functioning and psychological inflexibility, the investigators will conduct a randomized controlled trial with two conditions (LifeStories and waitlist control) using a sample of 90 adults currently taking antidepressant medication. Interested individuals will complete a screening survey to determine eligibility. After being informed about the study and potential risks, eligible participants who provide informed consent will be asked to complete a baseline survey. Participants will then be randomized to LifeStories or a waitlist control conditions, each lasting 4 weeks. Those in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to LifeStories modules. Participants in both groups will be asked to complete a midtreatment survey 2 weeks after baseline, and a posttreatment survey 4 weeks after baseline (i.e. after completing the 4-week video intervention for those in the active condition).
Participants (N=60) will be recruited from two racially diverse churches or senior centers (30 participants per church/center) to examine the efficacy of the HAIL Online platform + F\&S! program for older adults in black communities. Participants will complete the 8-week F\&S! exercise program (with access to the adjunct HAIL online platform), which will be delivered in-person as well as remote, and then continue to use the HAIL online platform during the 3-mo follow-up.
The current invention concerns new bioadhesive polymers incorporated with biodegradable components. The bioadhesive components used are polycarboxylic acids, while the biodegradable components can be any synthetic degradable polymers, particularly biodegradable polyesters whose degradation products are small molecular esters. The two polymer components may be covalently bound to each forming graft, block or random copolymers, examples of which include poly(acrylic acid)-graft-poly(lactic acid) (PAA-g-PLA) and pol(lactic-co-glycolic acid)-g-poly(acrylic acid) (PLGA-g-PAA). The two components may also be incorporated into one material by forming non-covalent interpolymer complex via, for examples, hydrogen bonding, ionic bonding or hydrophobic bonding. Typical examples in this category include the hydrogen bonding interpolymer complex formed between poly(methacrylic acid) and poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid) tri-block copolymers. The new materials may be used without a treatment agent to provide a lasting acidic pH environment or used with a treatment agent as a delivery system.
Effect of Omeprazole

Omeprazole is a substrate and an inhibitor of CYP2C19 in vivo, a substrate of CYP3A4 in vivo, and an inhibitor of CYP2C19 in vitro. Therefore, omeprazole may affect the metabolism and plasma concentrations of drugs that are metabolized by these CYP enzymes. Although in healthy subjects no interaction with theophylline or propranolol was reported, there have been reports of an interaction with other drugs metabolized via the CYP enzyme system (e.g., cyclosporine, disulfiram, benzodiazepines). Carefully monitor patients taking these drugs to determine if dosage adjustments of these drugs are necessary when taken concomitantly with omeprazole. 

Effect of Clarithromycin

Clarithromycin is a substrate and inhibitor of CYP3A enzymes. Coadministration of clarithromycin with drugs metabolized by CYP3A may be associated with elevations in drug concentrations that could increase the therapeutic and adverse effects of the concomitant drug. There have been reports of CYP3A-based interactions of erythromycin and/or clarithromycin with cyclosporine, tacrolimus, alfentanil, rifabutin, methylprednisolone, cilostazol, bromocriptine and lurasidone. OMECLAMOX_PAK is contraindicated in patients receiving lurasidone [see Contraindications (4.2)]. In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including: hexobarbital, phenytoin, and valproate.
PURPOSE:A dry coated tablet, prepared by specifying the radius of curvature of the surface of an inner core tablet coated with an enteric film and the radius of curvature of the outer layer, and capable of preventing the damage of the film in tableting the enteric film coated tablet as an inner core, and having improved acid resistance. CONSTITUTION:A dry coated tablet obtained by specifying the radius of curvature of the inner core tablet coated with an enteric film coating at 1.1 or more, preferably about 1.1-1.7, diameter ratio and the radius of curvature of the outer layer surface at about 0.4-0.9 diameter ratio. A chemical, e.g. an enzyme such as serratiopeptidase, pancreatin or lysozyme chloride. On the other hand, there is no limitation on the drug contained in the outer layer. The above-mentioned film coating will not be cracked nor damaged in the dry coated tablet, and the component in the dry coated tablet will not be decomposed nor inactivated by the acid in the stomach.
PURPOSE: Inclusion complexes of aryl-heterocyclic salts are provided to be soluble in hydrogenous cyclodextrine solution and to be administered by a small injection volume in case of administering non-orally as a hydrogenous solution to a patient. CONSTITUTION: Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrine. Preferred cyclodextrine are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrine inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40 % w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.
BACKGROUND: Nosocomial infections caused by Serratia marcescens mostly occurred in pediatrics and it was very rarely reported after adult surgery. Here, an intracranial abscess caused by Serratia marcescens was reported. We report a rare case of a postoperative intracranial abscess caused by Serratia marcescens in a 63-year-old male patient with a left parietal mass. The patient underwent resection of the mass on June 1, 2022, and the postoperative pathology revealed an angiomatous meningioma, WHO I. He then experienced recurrent worsening of right limb movements, and repeated cranial CT scans showed oozing blood and obvious low-density shadows around the operation area. Delayed wound healing was considered. Subsequently, a large amount of pus was extracted from the wound. The etiological test showed that Serratia marcescens infection occurred before the removal of the artificial titanium mesh. Antibiotics were initiated based on the results of drug susceptibility tests. At present, the patient is recovering well and is still closely monitored during follow-up.
CONCLUSION: It is rare for Serratia marcescens to cause brain abscesses without any obvious signs of infection. This report provided in detail our experience of a warning postoperative asymptomatic brain abscess caused by an uncommon pathogen.
A machine-learning-based prognostic and health management system includes a machine monitor, a command receiver, a processor, and an alarm. The machine monitor dynamically receives to-be-tested machine data that is associated with a to-be-tested machine’s operations. The command receiver dynamically receives a model assigning command. The processor dynamically applies a damage early warning machine learning model that is assigned via the model assigning command for processing the to-be-tested machine data to predict an anomaly probability that an anomaly occurs to the to-be-tested machine. Also, the processor generates a damage possibility warning dynamically according to the anomaly probability for determining whether to keep the to-be-tested machine running or not. The alarm indicates the anomaly probability according to the damage possibility warning and indicates whether to keep the to-be-tested machine running or not.
This is a dose escalation study which will escalate the dose of Cyberknife radiosurgery boost after external beam radiation of 45 Gy with concurrent capecitabine. The three dose levels are 4 Gy x5, 5 Gy x5 and 6 Gy x 5, with 3 patients at each dose level. Dose-limiting toxicity (DLT) is defined as acute grade 3 liver or intestinal toxicity or any acute grade 4 toxicity. If one patient experienced a DLT at a particular dose level, the cohort should be expanded to 6 patients. The maximum tolerated dose (MTD) is defined as the dose level below that which results in DLT in 2 or more of the 6 patients in each cohort. At least 5 patients should be enrolled in the cohort of 6 Gy x 5 even if none of the first 3 experienced DLT, as a means of added verification of dose tolerance, at this upper limit of dose for this study.

The patient population includes any patients who have unresectable hilar cholangiocarcinoma without any prior history of radiation. We anticipate accruing 1 patient every 2 months; therefore, we estimate that it will require approximately 22 months to accrue 11 patients if no DLT is experienced by any patients requiring expansion of the cohorts.
Empathic pain refers to an individual's perception, judgment, and emotional response to others' pain. This complex social cognitive ability is crucial for healthy interactions in human society. In recent years, with the development of multidisciplinary research in neuroscience, psychology and sociology, empathic pain has become a focal point of widespread attention in these fields. However, the neural mechanism underlying empathic pain remain a controversial and unresolved area. This review aims to comprehensively summarize the history, influencing factors, neural mechanisms and pharmacological interventions of empathic pain. We hope to provide a comprehensive scientific perspective on how humans perceive and respond to others' pain experiences and to provide guidance for future research directions and clinical applications. This article is part of the Special Issue on "Empathic Pain".
A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will first be ingested at rest (167 mL), right before starting warmup. Another dose (167 mL) will be administered after warmup. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
Protocol:

In this study, the demographic information (age, gender, body mass index, education level, occupation, etc.) of all participants will be recorded first. In the first evaluation, the participants' gait parameters will be determined by using the 10-meter walking test and the wearable sensors. Balance is evaluated by Functional Reach Test, One Leg Stand Test and Tinetti Balance and Gait Assessment. Cognitive skills will be evaluated by using Mini Mental Test and Stroop Test. After the first evaluations of the participants, the participants will be given single or dual task training for 6 weeks, 2 times a week, not on consecutive days. If participants are absent for any training session, a compensation training session will be organized for them. After completing the single and / or dual task training, the final evaluations will be made. Randomization will be performed according to age, gender and body mass index of participants. After the randomization, participants' training group will be determined. Warm-up and cooling exercises will be carried out between 5-10 minutes before and after each training. Each training will consist of approximately 45-60 minutes including warm-up and cooling exercise periods. Each exercise starts with 5 repetitions and proceeds to 10 repetitions. To reduce the effects of fatigue and to draw attention, a break time that consists of approximately 1-2 minutes will be given.

Statistical Analysis:

The effect size obtained in the reference study was strong (d = 1.16). As a result of the power analysis using the effect size value in the reference study for the study, it was calculated that 80% power could be obtained at 95% confidence level when at least 20 people (10 people per group) were included the study. The data will be analyzed with Statistical Package for the Social Sciences (SPSS) package program. Continuous variables will be given as mean ± standard deviation and categorical variables as number and percentage. In the independent group comparisons, if the parametrical test assumptions are obtained, independent samples t-test will be used if the parametric test assumptions are not obtained Mann Whitney U test will be used. In the dependent group comparisons, when the parametric test assumptions are obtained, paired samples t-test; if not obtained Wilcoxon tests will be used.
Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
The present invention relates to an antibacterial peptide derived from Bacillus tequilensis K1R and use thereof. According to the present invention, peptide K1R exhibits better results than vancomycin and bacitracin with respect to various kinds of multi-drug resistant (MDR) pathogenic bacteria, in particular, living organisms of a vancomycin-resistant Enterococcus group. An antagonistic effect of the antibacterial peptide against MDR pathogenic bacteria such as Salmonella typhimurium and Enterococcus sp. has been identified to have potential applicability thereof when K1R treats cases of MDR pathogenic bacteria. Antioxidant activity of K1R equals to antioxidant activity of standard ascorbic acid. Accordingly, the antibacterial peptide derived from Bacillus tequilensis K1R of the present invention has excellent antibacterial properties compared to a conventional antibacterial agent and thus can be advantageously used as an active ingredient of a pharmacological composition for antibacterial and antioxidant purposes.
This was an observational study so participants only took medication that was prescribed by their regular healthcare provider. No additional study medication was administered. This study enrolled patients who were previously diagnosed with moderate to very severe chronic obstructive pulmonary disease (COPD). This study looked at the prevalence of chronic bronchitis in patients suffering from moderate, severe or very severe COPD, and it also compared worsening of COPD in patients with or without chronic bronchitis. This study enrolled 976 patients. This multi-centre trial was conducted in Belgium and Luxembourg. The overall time to participate in this study was at a single, regularly scheduled visit at the pulmonologists office. There were no follow-up assessments for this study.